BioSpace News Archive

Spinal Elements ® Announces Full Commercial Launch of Luna ® XD and Orbit ™ Systems

Heat Biologics, Inc. today announced that Jeff Wolf, Chief Executive Officer of Heat Biologics, will be presenting at the Cantor Fitzgerald Global Healthcare Conference being held virtually between September 27-30, 2021.

OpGen, Inc. today announced clinical data from an investigator-initiated and driven prospective randomized controlled multicenter study.

Revolution Medicines, Inc. today announced that the company will participate in the upcoming 3rd Annual RAS-Targeted Drug Development Summit being held September 21-23, 2021.

Qualigen Therapeutics, Inc. announced today that CEO and Chairman Michael Poirier will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit September 20-23, 2021.

Today, Rapid Dose Therapeutics Corp. (“ RDT ” or the “ Company ”) ( CSE: DOSE ) and McMaster University (“ McMaster ”) are reporting a preliminary, yet significant milestone in the investigation of an orally delivered vaccine candidate for COVID-19.

Kyverna Therapeutics, Inc., today announced the appointment of Ian Clark as chair of the company’s board of directors and the appointment of Karen Walker as Chief Technology Officer (CTO).

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office has issued US Patent No. 11,097,102 to electroCore, relating to devices, systems and methods integrated with, or coupled to, smartphones that allow patients to self-treat medical conditions, such as migraine headache, by electrical non-invasive stimulation of nerves.

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, announced today that David Arthur, Chief Executive Officer, will present at the Life Science Investor Forum taking place September 16, 2021.

Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced the appointment of Laurent Goux as the General Manager of Europe.